PRMT5 and astrocytoma (excluding glioblastoma): Notably, IDH-mutant astrocytomas exhibiting both MGMTp methylation and elevated PRMT5 expression show significantly prolonged PFS with TMZ monotherapy compared to other subgroups (42).